Millennium Management
HRTX icon

Millennium Management’s Heron Therapeutics HRTX Stock Holding History

Millennium Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-200,000
Closed -$3.8M – 3333
2016
Q1 		$3.8M Buy
+200,000
New +$3.95M 0.01% 1412

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
CPC
Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return

Millennium Management's HRTX Position: Q1 2026 in Review

Millennium Management increased its Heron Therapeutics (HRTX) stake by 6.4% in Q1 2026, buying an estimated $534K and bringing the position to 7,630,527 shares worth $6.11M. The position accounts for ﹤0.01% of the portfolio, ranked #2719.

Millennium Management first reported a position in HRTX in Q1 2014 and has held it in 39 quarters since. The position peaked at $23.7M in Q2 2015. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Millennium Management held 7,630,527 shares of Heron Therapeutics worth $6.11M as of Q1 2026.
  • Millennium Management bought 460,619 Heron Therapeutics shares in Q1 2026, an estimated $534K.
  • Heron Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #2719 holding.
  • Millennium Management first reported a position in Heron Therapeutics in Q1 2014 and has held it in 39 quarters since.
  • Millennium Management's Heron Therapeutics position peaked at $23.7M in Q2 2015.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.